Here, we not only corroborate prior findings of clinically relevant, elevated levels of CXCL9 and CXCL10 in JDM patients, but we also demonstrate that their gene expression and production can be induced in vitro using human bioengineered myobundles. The gene discussed is CXCL9; the disease is juvenile dermatomyositis.